Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Median monthly launch price of a new anticancer drug,

Published byIlona Elstelä Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Median monthly launch price of a new anticancer drug,"— Presentation transcript:

1 Figure 2 Median monthly launch price of a new anticancer drug,
compared with median monthly household income from 1975–2014 in the USA Figure 2 | Median monthly launch price of a new anticancer drug, compared with median monthly household income from 1975–2014 in the USA. Data on household incomes were obtained from the 2015 United States Census130, and drug prices were obtained from Bach & Schnorr131. Prasad, V. et al. (2017) The high price of anticancer drugs: origins, implications, barriers, solutions Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 2 Median monthly launch price of a new anticancer drug,"

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Life expectancy at birth in all countries included

Figure 3 Life expectancy at birth in all countries included
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 5 Identification of mucinous carcinoma

Figure 5 Identification of mucinous carcinoma

Similar presentations

Ads by Google